# Left atrial appendage occlusion

Left atrial appendage occlusion (LAAO), also referred to as left atrial appendage closure (LAAC), is a procedure used to reduce the risk of blood clots from the left atrial appendage entering the bloodstream and causing a stroke in those with non-valvular atrial fibrillation.

## Rationale

The left atrial appendage is a pouch-like structure located in the upper part of the left atrium. Left atrial appendage occlusion (LAAO) is an alternative therapy to oral anticoagulation in a certain subset of patients with atrial fibrillation. Atrial fibrillation is characterized by an irregular and uncoordinated pumping function of the atria. This chaotic pattern of contraction can lead to reduced pumping efficiency and subsequent formation of blood clots, most notably in the left atrial appendage. Over 90% of stroke-causing clots that originate in the heart in patients with non-valvular AF are formed in the left atrial appendage. LAAO does not completely eliminate the risk of stroke in patients with AF but it does reduce the risk of stroke from emboli that originate in the left atrial appendage. The left atrial appendage can be purposefully occluded (i.e. closed) to help prevent the formation of clots in one of two ways.
* The Lariat procedure is a surgical procedure that can be performed to ligate the left atrial appendage from outside the heart.
* Endovascular implant is a catheter-based procedure used to place an occlusion device inside the orifice of the left atrial appendage.

## Indications

The most common treatment aimed at alleviating the burden of stroke in the setting of AF includes anticoagulation (blood-thinners), which are used to reduce the chance of blood clot formation. These medications, specifically direct oral anticoagulants (i.e. dabigatran, apixaban, rivaroxaban, edoxaban) and vitamin K antagonists (i.e. warfarin), are very effective in lowering the risk of stroke in AF patients. Most patients can tolerate anticoagulation for years (and even decades) without serious side effects. However, there are certain subsets of individuals who are unable to tolerate anticoagulation, and may be subject to increased bleeding or hematological risks. These patients may be good candidates for LAAO:
* Patients with poor anticoagulation therapy compliance (approximately 45% of patients who are eligible for warfarin are not being treated, due to tolerance or adherence issues)
* Patients with intolerable side effects to anticoagulation therapy
* Patients with chronic thrombocytopenia (low platelets) or a known coagulation defect associated with bleeding
* Patients with a prior history of severe bleeding (e.g., intracranial hemorrhage, major gastrointestinal bleeding)
* Patients with a high risk of falling or a history of prior falls that resulted in injury
* Patients with AF that are already undergoing cardiac surgery for other indications

## Devices and alternatives
### Surgical procedure
#### Lariat procedure

Occlusion of the left atrial appendage can be achieved from outside the heart (the Lariat device) or from inside the heart (endovascular) with a blood-exposed implant (the Watchman and Amulet devices). The first method is a form of ligation that eliminates perfusion of the LAA. While effective in preventing many embolic strokes, it also negates the endocrine contribution (atrial natriuretic peptide) of the LAA. The second approach has many hazards as well but preserves the cardiac endocrine properties of the LAA. Further evaluation of both approaches is merited.

#### Over-sewing

The LAA can also be surgically removed simultaneously with other cardiac procedures such as the maze procedure or during mitral valve surgery; specifically, it can be occluded or excluded by over-sewing, excision and resection, ligation, stapling with or without amputation of the LAA or application of a clip system Finally, the left atrial appendage has been closed in a limited number of patients using a chest keyhole surgery approach.

#### Clip devices

LAA can also be occluded by the placement of clips such as the AtriClip or Penditure devices.

### Catheter-based LAAC implant procedure
#### Watchman device

On March 13, 2015, the U.S. Food and Drug Administration approved the Watchman LAAC Implant, from Boston Scientific, to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular AF who are at increased risk of stroke have an appropriate reason to seek a non-drug alternative to blood thinning medications. The Watchman implant was studied in two randomized clinical trials and several clinical registries. The implant was approved in Europe in 2009.
The Watchman is a one-time implant typically performed under general anesthesia with transesophageal echo guidance (TEE). Similar to a stent procedure, the device is guided into the heart through a flexible tube (catheter) inserted through the femoral vein in the upper leg. The implant is introduced into the right atrium and is then passed into the left atrium through a hole in the septum that divides the two atria of the heart. This small hole in the septum usually disappear within six months. Once the position is confirmed, the implant is released and is left permanently fixed in the heart. The implant does not require open heart surgery and does not need to be replaced. Recovery typically takes twenty-four hours.
The patient continues taking warfarin with aspirin for 45 days post implantation at which point in time they return for a transesophageal echocardiography to judge completeness of the closure and the presence of blood clots. If the LAA is completely occluded, then the patient can stop taking warfarin and start clopidogrel and aspirin for six months after implant. At six months post implantation, it is recommended for the patient to continue taking aspirin indefinitely. In the PREVAIL clinical trial, 92% of patients stopped taking warfarin after 45 days and 99% discontinued warfarin at one year.
Another device termed PLAATO (percutaneous left atrial appendage transcatheter occlusion) was the first LAA occlusion device, although it is no longer being developed by its manufacturer (Appriva Medical, Inc. from Sunnyvale, California). In 210 patients receiving the PLAATO device, there was an estimated 61% reduction in the calculated stroke risk.

#### Amplatzer Amulet device

The Amplatzer device from St. Jude Medical, used to close atrial septal defects, has also been used to occlude the left atrial appendage. This can be performed without general anaesthesia and without echocardiographic guidance. Transcatheter patch obliteration of the LAA has also been reported. The Amulet device is inserted very similarly to the Watchman LAAC implant. A catheter is introduced into the groin and travels up to the heart where it crosses from the right atrium into the left atrium via a hole in the septum. The device is then discharged into the LAA. Eventually tissue grows over the Amulet device and completely occludes the LAA.
The ULTRASEAL LAA device, from Cardia, is a percutaneous, transcatheter device intended to prevent thrombus embolization from the left atrial appendage in patients who have non-valvular atrial fibrillation. As with all Cardia devices (such as: Atrial Septal Defect Closure Device or Patent Foramen Ovale Closure Device), the Ultraseal is fully retrievable and repositionable in the Cardia Delivery System used for deployment. The device can be retrieved and redeployed multiple times in a single procedure without replacing the device or delivery sheath.
Other devices exist to occlude the left atrial appendage from the inside of the heart such as the Wavecrest device and the Lariat device. The latter technique entails closing a strangling noose around the LAA, which is advanced from the chest wall with a special sheath, after introducing a balloon in the LAA from the inside surface of the heart (endocardium).

## Adverse events

The main adverse events related to these procedures include pericardial effusion, incomplete LAA closure, dislodgement of the device, blood clot formation on the device requiring prolonged oral anticoagulation, and the general risks of catheter-based techniques (such as air embolism). The left atrium anatomy can also preclude use of the device in some patients.
Theoretical concerns surround the role of the LAA in thirst regulation and water retention because it is an important source of atrial natriuretic factor. Preserving the right atrial appendage might attenuate this effect.

## Footnotes

* 1 2 "Left Atrial Appendage Closure Procedures". www.hopkinsmedicine.org. 2023-03-15. Retrieved 2023-11-05.
* ↑ Blackshear JL, Odell JA (February 1996). "Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation". Ann. Thorac. Surg. 61 (2): 755–759. doi:10.1016/0003-4975(95)00887-X. PMID 8572814.
* ↑ Baudo M, Rosati F, Benussi S (2024). "Surgical options for atrial fibrillation treatment during concomitant cardiac procedures". Annals of Cardiothoracic Surgery. 13 (2): 135–145. doi:10.21037/acs-2023-afm-0208. PMC 10998971. PMID 38590994.
* ↑ Yaghi, Shadi; Song, Christopher; Gray, William A.; Furie, Karen L.; Elkind, Mitchell S.V.; Kamel, Hooman (December 2015). "Left Atrial Appendage Function and Stroke Risk". Stroke. 46 (12): 3554–3559. doi:10.1161/STROKEAHA.115.011273. PMC 4659748. PMID 26508750.
* ↑ "UpToDate". www.uptodate.com. Retrieved 2023-11-05.
* ↑ Jani, et al. (April 2014). "Uptake of Novel Oral Anticoagulants in Patients with Non-Valvular and Valvular Atrial Fibrillation: Results from the NCDR-Pinnacle Registry", J Am Coll Cardiol 63 (12). Table 1.
* ↑ Crystal E, Lamy A, Connolly SJ, et al. (January 2003). "Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention". Am. Heart J. 145 (1): 174–178. doi:10.1067/mhj.2003.44. PMID 12514671.
* ↑ Healey JS, Crystal E, Lamy A, et al. (August 2005). "Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke". Am. Heart J. 150 (2): 288–293. doi:10.1016/j.ahj.2004.09.054. PMID 16086933.
* ↑ Thorsten Hanke, "Surgical management of the left atrial appendage: a must or a myth?", European Journal of Cardio-Thoracic Surgery, Volume 53, Issue suppl 1, April 2018, pp. i33–i38, doi:10.1093/ejcts/ezy088
* ↑ Johnson WD, Ganjoo AK, Stone CD, Srivyas RC, Howard M (June 2000). "The left atrial appendage: our most lethal human attachment! Surgical implications". Eur J Cardiothorac Surg. 17 (6): 718–722. doi:10.1016/S1010-7940(00)00419-X. PMID 10856866.
* ↑ Blackshear JL, Johnson WD, Odell JA, et al. (October 2003). "Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation". J. Am. Coll. Cardiol. 42 (7): 1249–1252. doi:10.1016/S0735-1097(03)00953-7. PMID 14522490.
* ↑ Watchman LAA Closure Technology – P130013. (US Food and Drug Administration), April 2015.
* ↑ P De Backer O, Arnous S, Ihlemann N, et al. (April 2014). "Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update". Open Heart. 1 (e000020): e000020. doi:10.1136/openhrt-2013-000020. PMC 4195925. PMID 25332785.
* 1 2 3 Watchman Left Atrial Appendage Closure Device with Delivery System Archived 2015-06-24 at the Wayback Machine. 14 (Boston Scientific), March 2015.
* 1 2 Onalan O, Crystal E (February 2007). "Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation". Stroke. 38 (2 Suppl): 624–630. doi:10.1161/01.STR.0000250166.06949.95. PMID 17261703.
* ↑ Schmidt H, Hammerstingl C, von der Recke G, Hardung D, Omran H (2006). "Long-term follow-up in patients with percutaneous left atrial appendage transcatheter occlusion system (PLAATO): risk of thrombus formation and development of pulmonary venous obstruction after percutaneous left atrial appendage occlusion". J. Am. Coll. Cardiol. 47: 36A.
* ↑ Holmes D, et al. (July 2014). "Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial". J. Am. Coll. Cardiol. 64 (1): 1–12. doi:10.1016/j.jacc.2014.04.029. PMID 24998121.
* ↑ Sievert H, Lesh MD, Trepels T, et al. (April 2002). "Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience". Circulation. 105 (16): 1887–1889. doi:10.1161/01.CIR.0000015698.54752.6D. hdl:2434/206370. PMID 11997272.
* ↑ Ostermayer SH, Reisman M, Kramer PH, et al. (July 2005). "Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials". J. Am. Coll. Cardiol. 46 (1): 9–14. doi:10.1016/j.jacc.2005.03.042. PMID 15992628.
* ↑ Bayard Y, Omran H, Kramer P, et al. (2005). "Worldwide experience of percutaneous left atrial appendage transcatheter occlusion (PLAATO)". J. Neurol. Sci. 238: S70. doi:10.1016/s0022-510x(05)80271-0. S2CID 54365763.
* ↑ Meier B, Palacios I, Windecker S, et al. (November 2003). "Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation". Catheterization and Cardiovascular Interventions. 60 (3): 417–422. doi:10.1002/ccd.10660. PMID 14571497. S2CID 2978865.
* ↑ Nietlispach F, Gloekler S, Krause R, Shakir S, Schmid M, Khattab AA, Wenaweser P, Windecker S, Meier B (2013). "Amplatzer left atrial appendage occlusion: Single center 10-year experience". Catheterization and Cardiovascular Interventions. 82 (2): 283–289. doi:10.1002/ccd.24872. PMID 23412815. S2CID 1895296.
* ↑ Health, Center for Devices and Radiological (2021-10-04). "Amplatzer Amulet Left Atrial Appendage Occluder – P200049". FDA.
* ↑ Cheng Yanping; McGregor Jenn; Sommer Robert (2012). "TCT-764 Safety and Biocompatibility of the Coherex WaveCrest™ Left Atrial Appendage Occluder in a 30-Day Canine Study". J Am Coll Cardiol. 60 (17S): B222–B223. doi:10.1016/j.jacc.2012.08.807.
* ↑ Bartus K, Han FT, Bednarek J (Jul 2013). "Percutaneous Left Atrial Appendage Suture Ligation Using the LARIAT Device in Patients With Atrial Fibrillation: Initial Clinical Experience". J Am Coll Cardiol. 62 (2): 108–118. doi:10.1016/j.jacc.2012.06.046. PMID 23062528.
* ↑ Sick PB, Schuler G, Hauptmann KE, et al. (April 2007). "Initial worldwide experience with the Watchman left atrial appendage system for stroke prevention in atrial fibrillation". J. Am. Coll. Cardiol. 49 (13): 1490–1495. doi:10.1016/j.jacc.2007.02.035. PMID 17397680.
* ↑ Fountain R, Holmes DR, Hodgson PK, Chandrasekaran K, Van Tassel R, Sick P (October 2006). "Potential applicability and utilization of left atrial appendage occlusion devices in patients with atrial fibrillation". Am. Heart J. 152 (4): 720–723. doi:10.1016/j.ahj.2006.05.001. PMID 16996847.
* ↑ Zimmerman MB, Blaine EH, Stricker EM (January 1981). "Water intake in hypovolemic sheep: effects of crushing the left atrial appendage". Science. 211 (4481): 489–491. Bibcode:1981Sci...211..489Z. doi:10.1126/science.7455689. PMID 7455689.
* ↑ Yoshihara F, Nishikimi T, Kosakai Y, et al. (August 1998). "Atrial natriuretic peptide secretion and body fluid balance after bilateral atrial appendectomy by the maze procedure". J. Thorac. Cardiovasc. Surg. 116 (2): 213–219. doi:10.1016/S0022-5223(98)70119-9. PMID 9699572.
* ↑ Omari BO, Nelson RJ, Robertson JM (August 1991). "Effect of right atrial appendectomy on the release of atrial natriuretic hormone". J. Thorac. Cardiovasc. Surg. 102 (2): 272–279. doi:10.1016/S0022-5223(19)36560-2. PMID 1830916.